Patients with metastatic or recurrent PTEN-loss/mutation squamous cell carcinomas (n = 3) and adenocarcinomas (n = 4) achieved a median OS of 6 months (95% CI, 2–10) and 11.3 months (95% CI, 0–22.6), respectively, similar to the median OS of those with metastatic or recurrent PTEN-intact squamous cell carcinoma (n = 21; 7 months, 95% CI, 3.1–10.9; p = 0.76) and adenocarcinoma (n = 16; 15.7 months, 95% CI, 7.1–24.3; p = 0.79), respectively (see Figure 5A and 5B). Here, PTEN is linked to adenocarcinoma.